Tag: Pharmacology Award

Mridul Guleria | Pharmacology | Best Researcher Award

Published on by World Science Awards

Best Researcher Award

Mridul Guleria — Guru Nanak Dev University

Mridul Guleria
Affiliation Guru Nanak Dev University
Country India
Scopus ID 59174404600
Documents 14
Citations 84
h-index 4
Subject Area Pharmacology
Event World Science Awards
ORCID 0009-0008-5898-8134

Mridul Guleria is a researcher affiliated with Guru Nanak Dev University, India, whose documented scholarly profile is associated with the field of pharmacology. The available bibliometric record identifies 14 documents, 84 citations, and an h-index of 4 in Scopus. [1] These indicators provide a concise quantitative view of the researcher’s indexed scholarly output and citation visibility.

This academic recognition profile presents the researcher’s research background, contributions, publication record, research impact, and suitability for consideration for the Best Researcher Award associated with the World Science Awards. The assessment is framed using the supplied bibliographic information and publicly identifiable researcher records rather than unsupported claims of distinction.

Abstract

Mridul Guleria is affiliated with Guru Nanak Dev University and works within the subject area of pharmacology. The researcher’s indexed profile records 14 documents, 84 citations, and an h-index of 4. [1] The profile is additionally associated with an ORCID identifier, providing a persistent scholarly identity record. [2] On the basis of the supplied academic indicators, the Best Researcher Award profile highlights scholarly productivity, citation-based visibility, subject-area relevance, and participation in research activities within pharmacology.

Keywords

Mridul Guleria; Best Researcher Award; pharmacology; pharmaceutical research; Guru Nanak Dev University; research impact; scholarly publications; citation analysis; Scopus; ORCID; World Science Awards.

Introduction

Pharmacology is a multidisciplinary area concerned with the study of drugs, their biological effects, mechanisms of action, therapeutic applications, and interactions with living systems. Research in this field contributes to the broader development and evaluation of pharmacological knowledge and can intersect with pharmaceutical sciences, biomedical research, toxicology, and related disciplines.

Within an academic recognition framework, researcher evaluation may consider several dimensions, including research productivity, publication activity, citation performance, subject relevance, originality, scholarly contribution, and broader research influence. Bibliometric databases such as Scopus can provide quantitative indicators for assessing indexed research output, while ORCID provides a persistent identifier that helps distinguish researchers and connect scholarly works with their authors. [1] [2]

Research Profile

The supplied research profile identifies Mridul Guleria as being affiliated with Guru Nanak Dev University in India and specializing in pharmacology.

These figures should be interpreted as a snapshot of the indexed research record and may change as databases update publication and citation information. [1]

Research Contributions

Mridul Guleria’s documented research specialization is pharmacology. The available record supports recognition of research activity within this subject area, while the supplied bibliometric indicators provide evidence of an established indexed publication and citation record. [1]

For academic evaluation purposes, the contribution profile can be considered across the following dimensions:

  • Subject-area engagement: Research activity is associated with pharmacology, a field relevant to drug research and biomedical science.
  • Scholarly productivity: Fourteen documents are recorded in the supplied Scopus profile.
  • Citation visibility: The supplied profile records 84 citations, indicating that indexed publications have received measurable scholarly referencing.
  • Research continuity: The presence of multiple indexed documents provides evidence of continuing scholarly publication activity.
  • Researcher identification: The association of Scopus and ORCID identifiers supports clearer attribution of scholarly work to the researcher. [1] [2]

Publications

The supplied Scopus record indicates 14 indexed documents associated with Mridul Guleria. [1] The available input does not provide a complete publication bibliography, individual article titles, journal names, publication dates, citation distributions, or DOI identifiers. Accordingly, no specific publication titles or DOI values are attributed here without bibliographic verification.

For a complete publication assessment, the Scopus author record and the researcher’s ORCID profile can be consulted to identify publications, author associations, and persistent scholarly records. [1] [2]

Research Impact

The supplied Scopus indicators show 84 citations across 14 documents and an h-index of 4. [1] These measures provide quantitative evidence of citation activity and scholarly visibility within the indexed research literature.

Citation counts and h-index values are useful indicators but should not be interpreted independently of publication context, career stage, discipline, authorship patterns, journal characteristics, or the nature of individual contributions. A balanced assessment of research impact therefore benefits from combining bibliometric information with qualitative evaluation of research originality, methodological quality, relevance, collaboration, and contribution to the field.

The presence of an ORCID identifier further supports persistent researcher identification and can facilitate the reliable association of scholarly outputs with the appropriate researcher. [2]

Award Suitability

The Best Researcher Award profile for Mridul Guleria is supported by the supplied evidence of academic affiliation, subject-area specialization, indexed publication activity, and citation performance. The World Science Awards provides the event context for this recognition. [3]

Based on the available information, relevant evaluation dimensions include:

  • Academic relevance: The researcher’s specialization in pharmacology aligns with a recognized scientific and biomedical research domain.
  • Publication record: Fourteen Scopus-indexed documents demonstrate measurable scholarly productivity. [1]
  • Citation performance: Eighty-four citations provide an observable indicator of scholarly attention to the indexed research output. [1]
  • h-index: An h-index of 4 provides an additional quantitative measure of citation distribution across the researcher’s indexed publications. [1]
  • Researcher identity: The availability of both Scopus and ORCID identifiers supports transparent scholarly attribution. [1] [2]

Taken together, these documented indicators provide a reasonable academic basis for consideration under a Best Researcher Award framework. Final award decisions, however, should be based on the official evaluation methodology, verified publication records, research quality, originality, and other criteria established by the awarding organization. [3]

Conclusion

Mridul Guleria is an India-based researcher affiliated with Guru Nanak Dev University whose documented research area is pharmacology. The supplied scholarly profile records 14 documents, 84 citations, and an h-index of 4 in Scopus, alongside an ORCID identifier that provides a persistent researcher identity. [1] [2]

The available evidence demonstrates measurable research productivity and citation visibility and provides a documented foundation for consideration for the Best Researcher Award at the World Science Awards. [3] Any final recognition should be determined through independent verification and the formal assessment criteria of the awarding body.

References

  1. Elsevier. (n.d.). Scopus author details: Mridul Guleria, Author ID 59174404600. Scopus.
    https://www.scopus.com/pages/authors/59174404600
  2. ORCID. (n.d.). ORCID record: Mridul Guleria, ORCID iD 0009-0008-5898-8134. ORCID.
    https://orcid.org/0009-0008-5898-8134
  3. World Science Awards. (n.d.). World Science Awards.
    https://worldscienceawards.com/

Mohammad Seyedabadi | Pharmacology | Best Researcher Award

Published on by World Science Awards

Best Researcher Award

Mohammad Seyedabadi, Mazandaran University of Medical Sciences
Mohammad Seyedabadi
Affiliation Mazandaran University of Medical Sciences
Country Iran
Scopus ID 24460920400
Documents 86
Citations 2,110
h-index 25
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-0044-8270

Mohammad Seyedabadi is a researcher affiliated with Mazandaran University of Medical Sciences in Iran, with a documented research specialization in pharmacology. The academic recognition presented in this article is the Best Researcher Award associated with the World Science Awards. The supplied research profile records 86 documents, 2,110 citations, and an h-index of 25. These bibliometric indicators provide a quantitative overview of the documented research record and are presented as profile information rather than as independent measures of scientific quality. Pharmacology encompasses the study of drugs, their mechanisms of action, therapeutic effects, adverse effects, and interactions with biological systems. [1][2]

Abstract

This article presents an academic recognition profile for Mohammad SEYEDABADI of Mazandaran University of Medical Sciences, Iran, in connection with the Best Researcher Award under the World Science Awards. The documented research subject is pharmacology, a biomedical discipline concerned with the properties, mechanisms, therapeutic applications, and safety of drugs and other bioactive substances. [1][2] The supplied bibliometric record identifies 86 documents, 2,110 citations, and an h-index of 25. These indicators suggest a substantial indexed research record within the supplied profile, while their interpretation should account for publication history, disciplinary citation practices, collaboration patterns, and the characteristics of individual publications. The award suitability discussion therefore considers the documented research specialization, publication volume, citation activity, and overall bibliometric profile without treating these measures as substitutes for qualitative assessment.

Keywords

  • Pharmacology
  • Drug discovery
  • Pharmacological research
  • Therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Biomedical science
  • Research impact

Introduction

Pharmacology is a central biomedical discipline that examines how chemical substances interact with living systems. It includes the study of drug mechanisms, pharmacodynamics, pharmacokinetics, therapeutic efficacy, adverse effects, and interactions. [1][2] Pharmacological research provides a scientific basis for understanding the actions of medicines and for supporting the development and evaluation of therapeutic interventions.

Modern pharmacology is closely connected with molecular biology, physiology, biochemistry, toxicology, medicinal chemistry, and clinical medicine. Research may range from investigations of molecular targets and signaling pathways to experimental evaluation of candidate compounds and clinical studies of therapeutic responses. The integration of these disciplines has contributed to the development of more selective treatments and improved understanding of drug response variability. [2][3]

Within this scientific context, Mohammad SEYEDABADI is identified in the supplied profile as a pharmacology researcher affiliated with Mazandaran University of Medical Sciences. The reported record of 86 documents, 2,110 citations, and an h-index of 25 provides a quantitative description of the indexed research profile. Further conclusions regarding specific scientific discoveries or therapeutic applications require examination of the underlying publications and verified research outputs.

Research Profile

Mohammad SEYEDABADI is affiliated with Mazandaran University of Medical Sciences in Iran. The supplied subject classification is pharmacology, placing the profile within the broader biomedical and pharmaceutical sciences. The reported combination of publication output and citation activity provides a bibliometric overview of the researcher’s indexed scholarly record. An h-index of 25 indicates that, within the supplied record, at least 25 publications have received at least 25 citations each, subject to the accuracy and coverage of the underlying database record. Bibliometric indicators should nevertheless be interpreted in their disciplinary and temporal context.

Research Contributions

The documented specialization of Mohammad SEYEDABADI is pharmacology. As a broad research field, pharmacology contributes to the scientific understanding of how therapeutic agents interact with biological targets and how those interactions influence physiological and pathological processes. [1][2] Pharmacological investigations may address molecular mechanisms, drug efficacy, safety, metabolism, therapeutic response, and interactions between medicines.

The supplied profile does not identify specific publication titles, experimental models, molecular targets, compounds, therapeutic areas, or clinical outcomes. Therefore, specific technical contributions are not attributed to the researcher beyond the documented subject classification. A detailed assessment of individual contributions would require review of the researcher’s publications and associated bibliographic records.

  • Research activity within the field of pharmacology.
  • Contribution to the indexed biomedical literature through a reported record of 86 documents.
  • Documented citation activity of 2,110 citations within the supplied profile.
  • A reported h-index of 25 as a measure of citation distribution within the indexed record.

These indicators describe scholarly output and visibility but do not by themselves establish the novelty, methodological quality, clinical relevance, or translational significance of individual studies.

Publications

The supplied research profile reports 86 documents and 2,110 citations. It does not provide a complete publication list, individual publication titles, journal information, publication dates, authorship details, or DOI identifiers for the researcher’s works. Consequently, no specific publication metadata are inferred in this article. For authoritative publication-level information, the researcher’s Scopus author record should be consulted directly. Database coverage, author disambiguation, citation counts, and document totals may change as indexing systems are updated.

Research Impact

The supplied profile reports 2,110 citations across 86 documents and an h-index of 25. These figures indicate that the indexed research record has received substantial citation activity within the reported database profile. Citation counts can provide evidence of scholarly visibility, although they do not by themselves measure research quality, reproducibility, clinical importance, or societal impact.

In pharmacology, research impact may arise through advances in understanding drug mechanisms, identification of biological targets, evaluation of therapeutic efficacy, characterization of safety profiles, or contributions to translational and clinical research. [1][2][3] The significance of a particular contribution therefore depends on the scientific question addressed, methodological rigor, reproducibility, and subsequent use of the findings.

For this profile, the available evidence supports a quantitative description of research impact based on document and citation counts and the reported h-index. Determining broader scientific or clinical impact would require additional evidence, such as highly cited publications, clinical translation, patents, guidelines, collaborations, or documented changes in research or healthcare practice.

Award Suitability

The Best Researcher Award profile is thematically aligned with Mohammad SEYEDABADI’s documented research specialization in pharmacology and the supplied record of scholarly output. The profile reports 86 documents, 2,110 citations, and an h-index of 25, providing several quantitative indicators that may be relevant when evaluating research activity and scholarly visibility.

The researcher is affiliated with Mazandaran University of Medical Sciences and is identified through Scopus Author ID 24460920400 and ORCID 0000-0003-0044-8270. These persistent identifiers provide mechanisms for distinguishing the researcher’s scholarly record and supporting bibliographic verification. On the basis of the supplied information, the profile provides a clear research-area match and a documented scholarly record that can support consideration for an award recognizing research activity. A formal award decision should additionally consider the official eligibility requirements, originality of research, methodological quality, peer-reviewed contributions, field-specific significance, and any qualitative criteria established by the World Science Awards.

Conclusion

Mohammad SEYEDABADI is identified in the supplied academic profile as a pharmacology researcher affiliated with Mazandaran University of Medical Sciences in Iran. The reported research record includes 86 documents, 2,110 citations, and an h-index of 25. These indicators provide a quantitative representation of the researcher’s indexed scholarly activity and citation visibility.

Pharmacology is an established biomedical field with direct relevance to drug mechanisms, therapeutic development, safety assessment, and clinical science. [1][2] The documented research specialization and bibliometric record provide a reasonable academic basis for an award profile focused on research achievement, while a comprehensive assessment of scientific distinction should incorporate publication-level evidence and qualitative evaluation in accordance with the applicable award criteria.

References

  1. Katzung, B. G., Vanderah, T. W. Basic & Clinical Pharmacology. McGraw Hill. This reference provides a general foundation for pharmacodynamics, pharmacokinetics, drug mechanisms, and therapeutic pharmacology.
  2. Brunton, L. L., Hilal-Dandan, R., Knollmann, B. C., eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw Hill. The text provides established principles concerning drug actions, therapeutic effects, mechanisms, and adverse reactions.
  3. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., Henderson, G. Rang & Dale’s Pharmacology. Elsevier. This reference covers pharmacological mechanisms and the relationship between drugs and biological systems.
  4. Scopus. Scopus Author Profile: Mohammad SEYEDABADI, Author ID 24460920400. The supplied profile identifies the researcher and reports the bibliometric information used in this article.
  5. ORCID. ORCID Record: Mohammad SEYEDABADI, ORCID 0000-0003-0044-8270. The persistent identifier is supplied as the researcher’s ORCID record.

The DOI references above are provided where applicable to support established scholarly literature. The researcher-specific bibliometric values in this article are based on the supplied profile information and should be checked against the current database records for the latest values.

Shakir Siddiqui | Pharmacology | Research Excellence Award

Published on by World Science Awards

Research Excellence Award

Shakir Siddiqui
Saras College of Pharmacy
Shakir Siddiqui
Affiliation Saras College of Pharmacy
Country India
Scopus ID 60706630600
Documents 2
Citations 1
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0009-0008-5328-8606

The Research Excellence Award recognizes scholarly contributions that demonstrate commitment to scientific research, academic development, and the advancement of knowledge within a defined discipline. Shakir Siddiqui, affiliated with Saras College of Pharmacy in India, has an emerging research profile in pharmacology supported by indexed scholarly publications and documented citation activity. The available bibliometric record provides an objective basis for describing his participation in the scientific literature.[1]

Abstract

Shakir Siddiqui is a researcher associated with Saras College of Pharmacy whose academic subject area is pharmacology. His available Scopus record comprises two indexed documents, one citation, and an h-index of one. These indicators represent an early-stage scholarly profile and demonstrate participation in formal scientific publication. Research in pharmacology contributes to the understanding of drugs, therapeutic mechanisms, safety, efficacy, and their applications in healthcare.[1][2]

Keywords

  • Pharmacology
  • Pharmaceutical Sciences
  • Drug Research
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Excellence
  • Health Sciences

Introduction

Pharmacology is a core biomedical discipline concerned with the study of medicines and their interactions with biological systems. It encompasses the mechanisms of drug action, pharmacokinetics, pharmacodynamics, therapeutic applications, adverse effects, and the development of evidence-based approaches to medication use. Research in this area supports the discovery and evaluation of treatments and contributes to improved healthcare practice.[2]

Research Profile

The available Scopus information identifies Shakir Siddiqui under the subject area of Pharmacology and records two indexed documents, one citation, and an h-index of one. These bibliometric measures indicate participation in scholarly research and provide a quantitative snapshot of the researcher’s current publication and citation activity.[1]

  • Affiliation: Saras College of Pharmacy.
  • Country: India.
  • Primary subject area: Pharmacology.
  • Scopus-indexed documents: 2.
  • Citations: 1.
  • h-index: 1.

Research Contributions

The researcher’s documented scholarly activity is situated within pharmacology and the broader pharmaceutical sciences. Research in these fields supports scientific understanding of therapeutic agents, biological responses, drug safety, and clinical applications. Contributions through peer-reviewed publication provide mechanisms for communicating findings to the wider scientific community and for supporting subsequent research.[2][3]

Publications

Shakir Siddiqui has two documents indexed in Scopus according to the supplied researcher profile. The indexed publication record represents scholarly dissemination within an internationally recognized bibliographic database. Continued publication and collaboration can provide opportunities for further development of research visibility and contribution to pharmacological literature.[1]

  • Indexed scholarly documents.
  • Pharmacology-related research.
  • Scientific communication through academic publications.
  • Participation in pharmaceutical and biomedical research.

Research Impact

Research impact can be considered through multiple dimensions, including publication quality, citation activity, methodological contribution, collaboration, and relevance to scientific or clinical practice. The current bibliometric profile records one citation and an h-index of one, providing measurable evidence of scholarly uptake within the indexed literature. These metrics should be interpreted in the context of publication volume and the researcher’s stage of academic development.[1]

Award Suitability

Based on the supplied academic information, Shakir Siddiqui demonstrates scholarly engagement in pharmacology through indexed research publications and documented citation activity. These characteristics may be considered as part of an award evaluation focused on research excellence. The World Science Awards may assess nominees using broader criteria such as research quality, originality, professional contribution, publication record, and potential impact; therefore, bibliometric indicators should be considered alongside qualitative evidence when evaluating award suitability.[1][4]

Conclusion

Shakir Siddiqui has established an emerging academic profile in pharmacology through participation in indexed scientific research. The available record of two Scopus documents, one citation, and an h-index of one provides a concise quantitative representation of his current scholarly activity. His affiliation with Saras College of Pharmacy places his research within the academic and pharmaceutical sciences environment, where continued investigation and publication can contribute to the development of evidence-based knowledge.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Shakir Siddiqui, Author ID 60706630600. Scopus.
    https://www.scopus.com/pages/authors/60706630600
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw Hill.
    DOI: https://doi.org/10.1036/9781259588331
  3. Katzung, B. G., Vanderah, T. W. Basic & Clinical Pharmacology. McGraw Hill.
    DOI: https://doi.org/10.1036/9781260463325
  4. World Science Awards. (n.d.). Official Award Information.
    https://worldscienceawards.com/

Vibhu Sahani | Pharmacology | Lifetime Achievement Award

Published on by World Science Awards

Lifetime Achievement Award

Vibhu Sahani
LLRM Medical College, Meerut
Vibhu Sahani
Affiliation LLRM Medical College, Meerut
Country India
Scopus ID 59031594100
Documents 7
Citations 8
h-index 1
Subject Area Pharmacology
Event World Science Awards

The Lifetime Achievement Award recognizes sustained academic service, scholarly engagement, and professional contributions within a scientific discipline. Vibhu Sahani of LLRM Medical College, Meerut has contributed to the field of pharmacology through research, scholarly publication, and academic activities. The available bibliometric information indicates participation in peer-reviewed scientific communication and ongoing involvement in pharmacological research.[1]

Abstract

Vibhu Sahani is an academic associated with LLRM Medical College, Meerut, India, whose scholarly work is focused on pharmacology. His published research contributes to the understanding of pharmacological science and supports continued advancement in medical research. Available bibliometric indicators, including indexed publications and citations, reflect participation in the international scientific literature and ongoing academic engagement.[1][2]

Keywords

  • Pharmacology
  • Drug Research
  • Medical Science
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Impact
  • World Science Awards

Introduction

Pharmacology is a multidisciplinary scientific field dedicated to understanding the mechanisms, therapeutic applications, efficacy, and safety of medicinal compounds. Research in pharmacology contributes significantly to disease prevention, treatment innovation, and evidence-based healthcare. Academic researchers working in this discipline support advances through laboratory investigations, clinical studies, and scientific publication.[3]

Research Profile

Based on the available Scopus data, Vibhu Sahani has authored seven indexed documents, received eight citations, and holds an h-index of one. These bibliometric indicators demonstrate participation in scholarly research and publication within pharmacology while contributing to the scientific literature through peer-reviewed academic work.[1]

  • Affiliation with LLRM Medical College, Meerut.
  • Primary research area: Pharmacology.
  • Indexed scientific publications: 7.
  • Total citations: 8.
  • Scopus h-index: 1.

Research Contributions

The available publication record indicates contributions to pharmacological investigations and medical science. Research activities in this field support the understanding of therapeutic interventions, drug action, patient care, and evidence-based medicine. Such scholarly contributions form an important part of continued scientific development in healthcare disciplines.[2][3]

Publications

The researcher’s publication portfolio includes peer-reviewed scientific articles indexed within international scholarly databases. These publications demonstrate participation in academic research and dissemination of scientific findings relevant to pharmacology and associated biomedical disciplines.[1]

  • Peer-reviewed journal publications.
  • Pharmacological and biomedical research.
  • Scientific collaboration and academic dissemination.
  • Indexed scholarly contributions.

Research Impact

Research impact is commonly evaluated through publication output, citation performance, scholarly visibility, and contribution to scientific knowledge. The available metrics indicate that Vibhu Sahani has established an indexed research presence in pharmacology. These bibliometric indicators provide objective evidence of participation in scholarly communication while supporting continued academic development.[1]

Award Suitability

Based on the information provided, Vibhu Sahani demonstrates academic engagement through research publication, institutional affiliation, and contributions to pharmacology. Consideration for recognition within the World Science Awards may acknowledge sustained scholarly participation and professional service. Final award decisions should be based on the complete evaluation criteria established by the organizing committee, including academic achievements, research quality, professional experience, and broader scientific contributions.[1][2]

Conclusion

Vibhu Sahani has contributed to pharmacological research through scholarly publication and academic engagement at LLRM Medical College, Meerut. His indexed research record reflects participation in scientific communication and supports ongoing advancement within the biomedical sciences. The documented academic profile provides an objective overview of research activity relevant to professional recognition in the scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Vibhu Sahani, Author ID 59031594100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59031594100
  2. World Science Awards. (n.d.). Recognition of scientific excellence through international academic awards.
    https://worldscienceawards.com/
  3. Goodman & Gilman’s. The Pharmacological Basis of Therapeutics.
  4. Nature Reviews Drug Discovery. Drug discovery and pharmacological innovation.
    DOI: https://doi.org/10.1038/nrd.2017.232

Ved Pal | Pharmacology | Innovative Research Award

Published on by World Science Awards

Innovative Research Award

Ved Pal
Affiliation ISF College of Pharmacy, Moga, Punjab
Country India
Scopus ID 59895257200
Documents 3
Citations 5
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-3523-1469

Ved Pal
ISF College of Pharmacy, Moga, Punjab, India

The Innovative Research Award recognizes researchers whose scholarly activities demonstrate sustained commitment to scientific advancement, innovation, and academic excellence. VED PAL, affiliated with ISF College of Pharmacy, Moga, Punjab, has established an academic profile in the field of pharmacology through research contributions, professional engagement, and participation in internationally recognized scholarly platforms.[1]

Abstract

VED PAL is an academic researcher associated with ISF College of Pharmacy, Moga, Punjab, India. His scholarly interests are centered on pharmacology, an interdisciplinary field that integrates pharmaceutical sciences, biomedical research, and therapeutic innovation. His academic profile reflects ongoing engagement with scientific publication, research dissemination, and professional development within the pharmaceutical sciences.[1][2]

Keywords

Pharmacology, Pharmaceutical Sciences, Drug Research, Biomedical Science, Therapeutics, Academic Research, Scientific Publications, Innovation, World Science Awards, Healthcare Research.

Introduction

Pharmacology remains one of the most significant scientific disciplines supporting healthcare innovation through the study of medicines, therapeutic mechanisms, and biological responses. Researchers working in this field contribute toward improving evidence-based healthcare, advancing pharmaceutical technologies, and supporting interdisciplinary scientific collaboration. Academic recognition programs acknowledge these contributions by evaluating research quality, scholarly productivity, and scientific impact using internationally recognized academic indicators.[2][3]

Research Profile

VED PAL is affiliated with ISF College of Pharmacy in Punjab, India, where his academic interests align with pharmacological research and pharmaceutical sciences. His scholarly identity is represented through internationally recognized researcher identifiers, including a Scopus Author ID and an ORCID profile, supporting transparency in research attribution and academic visibility.[1][4]

Research Contributions

Research activities in pharmacology typically involve investigations related to drug discovery, therapeutic evaluation, pharmacodynamics, pharmacokinetics, toxicology, and clinical relevance. Through academic participation and publication activities, VED PAL contributes to the broader scientific dialogue supporting pharmaceutical research and evidence-driven healthcare. Such contributions encourage collaboration between academic institutions and the scientific community while promoting responsible research practices.[2][5]

Publications

The researcher’s scholarly output is indexed through the Scopus author profile associated with Author ID 59895257200. Publication records, citation data, and bibliographic information are maintained through recognized academic indexing systems, allowing researchers and institutions to monitor scientific productivity and collaboration.[1]

Research Impact

Research impact extends beyond publication volume and includes scientific influence, collaboration, knowledge dissemination, and practical application of research findings. International researcher identifiers such as ORCID and Scopus improve research discoverability, strengthen scholarly communication, and facilitate accurate attribution across academic databases. These systems support transparent evaluation of academic achievements within the global research ecosystem.[1][4]

Award Suitability

The Innovative Research Award recognizes researchers demonstrating commitment to scholarly excellence, ethical research practices, scientific innovation, and meaningful contributions within their discipline. Based on the available academic identifiers, institutional affiliation, and specialization in pharmacology, VED PAL represents a researcher whose profile aligns with the objectives of recognizing ongoing scientific engagement and academic development through the World Science Awards.[5]

Conclusion

VED PAL’s academic profile reflects continued participation in pharmaceutical research and international scholarly communication. Through institutional affiliation, recognized researcher identifiers, and engagement with pharmacological sciences, the profile illustrates a commitment to research integrity, scientific advancement, and professional development. Recognition through the Innovative Research Award highlights the importance of sustained contributions to contemporary scientific research while encouraging future innovation within the pharmaceutical sciences.[1][5]

References

  1. Elsevier. (n.d.). Scopus Author Details: VED PAL, Author ID 59895257200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59895257200
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
    DOI: https://doi.org/10.1038/s41573-021-00234-4
  3. World Health Organization. (n.d.). Research for Health.
    https://www.who.int
  4. ORCID. (n.d.). ORCID Record: 0000-0003-3523-1469.
    https://orcid.org/0000-0003-3523-1469
  5. World Science Awards. (n.d.). Award Evaluation and Recognition Framework.
    https://worldscienceawards.com/

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Published on by World Science Awards

Dr. Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India

Dr. Gollapalle L. Viswanatha is a distinguished pharmacologist and toxicologist with over 17 years of expertise in pharmaceutical R&D, regulatory toxicology, and preclinical research. Currently serving as a Manager at ClinChoice Pvt. Ltd., Bengaluru, he has held pivotal roles in organizations like IQVIA, The Himalaya Drug Company, and Connexios Life Sciences. A prolific academic and industry contributor, Dr. Viswanatha has authored over 100 peer-reviewed articles and delivered more than 20 expert talks in global forums. As a DABT-certified and European Registered Toxicologist (ERT), his work bridges cutting-edge science with regulatory excellence. He also serves as adjunct faculty at Manipal College of Pharmaceutical Sciences, mentoring postgraduate students and contributing to academic research. His pioneering efforts in herbal drug evaluation, regulatory documentation, and systematic reviews make him a leading voice in toxicology and pharmacology. With several novel animal models to his credit, he actively influences drug discovery and translational medicine.

Professional Profile

Educational 

Dr. Viswanatha holds a PhD in Pharmaceutical Sciences (2019) from JNTU Anantapur, with a dissertation focused on indigenous medicinal plants against stroke and epilepsy. He is board-certified by the American Board of Toxicology (DABT, 2023) and recognized as a European Registered Toxicologist (ERT, 2022). He completed a PG Diploma in Statistical Quality Control and earned a Six Sigma Green Belt from the Indian Statistical Institute (ISI), Bengaluru in 2017, both with Grade ‘A’. He holds an M. Pharm in Pharmacology (2008) from RGUHS, Bengaluru, graduating with 77% and was honored as the Best Outgoing Student. Additionally, he is a GATE and GPAT qualifier. His academic foundation is marked by a multidisciplinary understanding of pharmacology, quality systems, and toxicology. Throughout his academic journey, he has demonstrated a commitment to both practical research and methodological rigor, blending statistical competence with clinical relevance in drug discovery and safety sciences.

Professional Experience

Dr. Viswanatha has a robust professional background spanning regulatory toxicology, preclinical pharmacology, and data surveillance. Currently, he leads the toxicology division at ClinChoice Pvt. Ltd. (2021–present), overseeing cosmetic ingredient safety, CTD preparation, biocompatibility risk assessments, and toxicological risk evaluations. He formerly worked at IQVIA India Pvt. Ltd. (2014–2021) as a Senior Medical Data Reviewer, specializing in clinical trial surveillance and protocol compliance for myocardial infarction studies. Prior to that, he served as a Research Associate at The Himalaya Drug Company (2010–2014), standardizing herbal drug models, and as a Scientist at Connexios Life Sciences (2008–2010), handling PK, safety pharmacology, and toxicological assessments of NCEs. His interdisciplinary approach combines GLP compliance, regulatory documentation, safety evaluations, and project leadership. With broad expertise across pharmaceuticals, nutraceuticals, and cosmetics, he has contributed to product development from discovery to regulatory submission while mentoring cross-functional teams and managing end-to-end project execution.

Awards and Honors 

Dr. Viswanatha has received numerous accolades throughout his academic and professional journey. He was honored with the prestigious Joe-Mae International Young Scientist Award by the AMS Society in Hong Kong (2016) and was a nominee for the Dr. Achari Award at IPSCON 2012 for his work on a novel pharyngitis animal model. He earned the title of Best Outgoing Student during his M. Pharm (2006–2008) and successfully qualified in GATE 2007, GPAT 2010 & 2011. His innovative contributions include the development of novel animal models for non-infectious pharyngitis and hemorrhoids. He has been invited for over 10 expert talks, delivered 5 hands-on workshops, and reviewed articles for over 35 high-impact journals, reflecting his standing as a respected thought leader. These honors underscore his commitment to translational pharmacology, scientific innovation, and academic mentorship, bridging traditional medicine with modern pharmacological practices.

Research Interests 

Dr. Viswanatha’s research interests span preclinical pharmacology, regulatory toxicology, herbal medicine, and evidence-based drug evaluation. His work focuses on stroke, epilepsy, neurodegeneration, nephroprotection, pharyngitis, and gastrointestinal and cardiovascular pharmacology, often using rodent models. He has a strong inclination toward toxicological risk assessment (TRA), biocompatibility studies, and regulatory documentation for pharmaceuticals and cosmetics. His current pursuits involve systematic reviews and meta-analyses on both clinical and preclinical data, particularly emphasizing GABAergic modulation, anti-inflammatory agents, and flavonoids like naringin. He also contributes to safety pharmacology and real-world evidence generation. Beyond therapeutic investigations, he’s deeply involved in OECD-compliant toxicology, SCCS cosmetic safety dossiers, and ISO 10993-based device safety evaluations. His dual strength in bench science and regulatory frameworks makes his research both impactful and implementation-ready, aligning traditional pharmacological principles with global safety standards.

Research Skills

Dr. Viswanatha possesses advanced skills in in vivo and in vitro pharmacological/toxicological experimentation, including GLP-compliant animal models using rats, mice, rabbits, and guinea pigs. He is proficient in conducting acute, repeated dose, and genotoxicity studies, and safety pharmacology evaluations per ICH guidelines. He excels in meta-analysis and systematic reviews using RevMan, RoB-2, G-Power, and Newcastle-Ottawa scales, alongside regulatory documentation (CTD modules 2.4 & 2.6, CPSR, ADE/PDE/OEL assessments). He has expertise in SCCS guidelines, QSAR & AOT software tools, and data analysis using GraphPad Prism, SPSS, and Minitab. He’s also skilled in toxicological literature mining using PubMed, ECHA, PubChem, and other databases. A Six Sigma Green Belt and SQC professional, his approach blends quality systems with analytical rigor. His research strengths lie in project management, protocol development, real-world evidence integration, and regulatory toxicology strategy, making him an asset across life sciences domains.

Conclusion

Dr. Viswanatha exemplifies a rare blend of rigorous experimental pharmacology and robust regulatory toxicology. His multidisciplinary education and certifications, from PhD to international toxicology credentials, underpin his leadership in both academic and industry domains. With a strong track record in innovative animal model development, systematic reviews, and regulatory documentation, he drives preclinical-to-clinical translation effectively. His prolific publication record, awards, and advisory roles highlight a distinguished career that continues to influence global life sciences.

 Publication Top Notes

  • 🧠 Clinical study on cisplatin‑induced nephrotoxicity in humans – PA Arunkumar et al. (2012)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn: A review – D Manohar et al. (2012)

  • 🍃 Antioxidant & anti-inflammatory activity of Mangifera indica leaf extracts – CG Mohan et al. (2013)

  • 🍊 Naringin’s neuroprotective neurobehavioral review/meta-analysis – GL Viswanatha et al. (2017)

  • 🍎 Isolation of antidiabetic principle from Punica granatum rinds – V Jain et al. (2012)

  • 🌳 POG‑glucose inhibits 11β‑HSD‑1 & ameliorates diet-induced diabetes – CG Mohan et al. (2013)

  • 🍋 Lemongrass oil for dexamethasone-induced hyperlipidemia – VRS Kumar et al. (2011)

  • 💊 Hepatoprotective activity of Hepax polyherbal formulation – VC Devaraj et al. (2011)

  • 🌿 Antioxidant & antimutagenic activities of Terminalia arjuna bark – GL Viswanatha et al. (2013)

  • 🩸 Rat model of hemorrhoids: anti‑hemorrhoidal study – M Azeemuddin et al. (2014)

  • 💧 LC‑MS/MS quantification of flavonoids in Moringa & Raphinus – VC Devaraj et al. (2011)

  • 🧠 Animal models of chemotherapy‑induced cognitive decline – J John et al. (2021)

  • 💡 Bacopa monnieri + rivastigmine memory reversal in rats – AHM Thippeswamy et al. (2016)

  • 🍊 Hesperidin’s neuroprotective & mitochondrial benefits – GL Viswanatha et al. (2012)

  • ⚡ Anti‑epileptic activity of Punica granatum leaf extracts – GL Viswanatha et al. (2016)

  • 🌲 Anxiolytic & anticonvulsant activity of Cedrus deodara – GL Viswanatha et al. (2009)

  • 🧠 POG‑glucose alleviates ischemia/reperfusion brain injury – GL Viswanatha et al. (2013)

  • 🧪 Anti‑ulcer effect of Raphinus sativus leaves – VC Devaraj et al. (2011)

  • 🌱 Gymnema sylvestre extract improves glucose uptake – PM Kumar et al. (2016)

  • 🍇 Phytochemical standardization of Punica granatum – V Jain et al. (2011)

  • 🌸 Anti‑fertility activity of Tabernaemontana divaricata flowers – MA Mukhram et al. (2012)

  • 🧊 Anti‑urolithiatic effect of Cedrus deodara extract – N Krishnadas et al. (2010)

  • 💩 Antidiarrheal activity of Thespesia populnea bark fractions – GL Viswanatha et al. (2011)

  • 🦴 Anti‑osteoporotic effect of herbal formula NR/CAL/06 – P Srikanta et al. (2011)

  • 🌿 Antidiarrheal activity of Lepidium sativum seed extract – D Manohar et al. (2011)

  • 🧠 Acteoside from Colebrookea – anti‑epileptic effects – GL Viswanatha et al. (2016)

  • 💊 Thienotriazines: synthesis & antihistaminic activity – GL Viswanatha et al. (2012)

  • 🧠 Punica granatum extract protects against I/R brain injury – GL Viswanatha et al. (2014)

  • 🌱 Colebrookea oppositifolia root for stroke – cerebroprotective effect – GL Viswanatha et al. (2019)

  • 💥 Anticonvulsant activity of POG‑glucose from Mangifera indica – GL Viswanatha et al. (2018)

  • 💊 Mechanisms of biochanin‑A: a pharmacological review – PV Anuranjana et al. (2010)

  • 🧬 Diabetic wound healing: update – R Keni et al. (2012)

  • 🛡️ Cardioprotective preclinical systematic review on naringin – GL Viswanatha et al. (2023)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn. review – M Divanji et al. (2022)

  • 🧠 Erythrina variegata bark extract: anxiolytic & anticonvulsant – G Pitchaiah et al. (2023)

 

Serkan Yigitkan | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Serkan Yigitkan | Pharmaceutical Science | Best Researcher Award

Dicle University, Turkey

Dr. Serkan Yiğitkan is a distinguished pharmacognosist affiliated with Dicle University’s Institute of Health Sciences in Diyarbakır, Turkey. His academic journey is marked by a profound dedication to the study of medicinal plants and their applications in healthcare. With a robust portfolio of 18 publications and a significant number of citations, Dr. Yiğitkan has established himself as a leading figure in his field. His research primarily focuses on the pharmacological properties of natural products, aiming to bridge the gap between traditional herbal remedies and modern medicine. Through his work, he seeks to validate and harness the therapeutic potentials of phytochemicals, contributing to the development of novel treatments for various ailments.

Professional Profile

Education

Dr. Yiğitkan completed his doctoral studies in pharmacognosy at Dicle University, where he delved into the chemical and biological properties of medicinal plants. His education provided a solid foundation in understanding the complexities of plant-based compounds and their interactions within biological systems. This academic background has been instrumental in shaping his research trajectory, allowing him to explore the vast potential of phytochemicals in therapeutic applications. His commitment to continuous learning and research is evident in his contributions to the scientific community, particularly in the realm of natural product pharmacology.

Professional Experience

Throughout his career, Dr. Yiğitkan has been actively involved in various research projects and academic collaborations. His role at Dicle University encompasses both teaching and research, where he mentors students and leads studies on the pharmacological effects of medicinal plants. His professional journey is characterized by a dedication to advancing the understanding of natural products and their potential therapeutic benefits. Through his involvement in numerous studies and publications, he has contributed significantly to the field of pharmacognosy, particularly in exploring the antimicrobial and antioxidant properties of plant extracts.

Research Interests

Dr. Yiğitkan’s research interests are centered around the pharmacological evaluation of medicinal plants, with a particular focus on their antimicrobial and antioxidant properties. He is keenly interested in identifying bioactive compounds that can serve as potential therapeutic agents. His work often involves the extraction and characterization of phytochemicals, aiming to discover novel compounds with significant health benefits. By investigating the traditional uses of plants and validating their efficacy through scientific methods, he contributes to the integration of herbal medicine into modern therapeutic practices.

Research Skills

Dr. Yiğitkan possesses a diverse set of research skills, including expertise in chromatographic techniques, bioassay-guided fractionation, and the evaluation of biological activities of natural products. His proficiency in these methodologies enables him to isolate and identify active compounds from complex plant matrices effectively. Additionally, his skills in designing and conducting experiments related to antimicrobial and antioxidant assays have been pivotal in advancing his research objectives. His methodological approach ensures the reliability and reproducibility of his findings, contributing to the broader scientific understanding of medicinal plants.

Awards and Honors

While specific awards and honors are not detailed in the available information, Dr. Yiğitkan’s contributions to the field of pharmacognosy are evident through his extensive publication record and the impact of his research. His work has garnered attention within the scientific community, reflecting his commitment to advancing knowledge in natural product research. The recognition of his studies by peers and the inclusion of his research in reputable journals underscore his standing as a respected scientist in his field.

Conclusion

Dr. Serkan Yiğitkan’s dedication to exploring the medicinal properties of plants has significantly enriched the field of pharmacognosy. His research endeavors have not only advanced scientific understanding but also paved the way for the development of novel therapeutic agents derived from natural sources. Through his meticulous studies and commitment to integrating traditional knowledge with modern science, Dr. Yiğitkan exemplifies the vital role of researchers in bridging cultural heritage and contemporary medicine. His ongoing efforts continue to inspire and contribute to the global appreciation of plant-based therapeutics.

Publications Top Notes

  1. Title: Assessment of the Anti-Acne Properties of Some Medicinal Plants and Development of an Herbal Anti-Acne Formulation
    Authors: F. Sezer Senol Deniz, Ozlem Oyardı, Cagla Bozkurt Guzel, Tahir Emre Yalcın, Serkan Yiğitkan, Yuksel Kan, Nurver Ulger Toprak, Ilkay Erdogan Orhan
    Year: 2025

  2. Title: LC-MS/MS Analysis and Biological Activities of Different Parts of Ziziphora capitate L.
    Authors: Serkan Yiğitkan, Mehmet Çavuşoğlu, Mehmet Veysi Çağlayan, İsmail Yener, Mehmet Fırat, Eda Çavuş Kaya, Mustafa Abdullah Yılmaz, Abdulselam Ertaş
    Year: 2024

  3. Title: Ziziphora clinopodioides Lam. Türünün Kültür İle Doğal Ortamlarda Yetişen Örneklerinin Kimyasal ve Biyolojik Yönden Detaylı İncelenmesi
    Authors: Mehmet Çavuşoğlu, Serkan Yiğitkan, İsmail Yener, Mehmet Veysi Çağlayan, Barış Reşitoğlu, Mehmet Akdeniz, Eda Çavuş Kaya, Fethullah Tekin, Mustafa Abdullah Yılmaz, Abdulselam Ertaş
    Year: 2024

  4. Title: A Comprehensive Study on Chemical and Biological Investigation of Thymus Brachychilus Jalas: A Rich Source of Ursolic and Oleanolic Acids
    Authors: Mehmet Akdeniz, Serkan Yiğitkan, Mustafa Abdullah Yılmaz, İsmail Yener, Elif Varhan Oral, Mehmet Fırat, Ilkay Erdogan Orhan, Ufuk Kolak, Abdulselam Ertaş
    Year: 2024

  5. Title: Essential Oil Contents and Biological Activities of Thymus Canoviridis Jalas and Thymus Sipyleus Boiss.
    Authors: Serkan Yiğitkan, Mehmet Fırat
    Year: 2024

  6. Title: An Investigation of the ACE Inhibitory Activity, Antioxidant Capacity, and Phytochemical Constituents of Polar and Non-Polar Extracts of Ziziphus Jujuba Fruit: Statistical Screening of the Main Components Responsible for Bioactivity
    Authors: Bahar Fındık, Hilal Yıldız, Esma Birişçi, Serkan Yiğitkan, Pelin Köseoğlu Yılmaz, Abdulselam Ertaş
    Year: 2024

  7. Title: Comprehensive Study of Chemical Composition and Biological Activity of Thymus pubescens Boiss. et Kotschy ex Čelak.
    Authors: Serkan Yiğitkan, Mehmet Akdeniz, İsmail Yener, Zeki Seker, Mustafa Abdullah Yılmaz, Mehmet Fırat, Deniz Evrim Kavak, Pelin Yılmaz Köseoğlu, Abdulselam Ertaş, Ufuk Kolak
    Year: 2022

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1